Related Experiment Video
Updated: Jul 15, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Add-on amlodipine improves arterial function and structure in hypertensive patients treated with an angiotensin
Atsuhiro Ichihara1, Yuki Kaneshiro, Mariyo Sakoda
1Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. atzichi@sc.itc.keio.ac.jp
Insights
Adding amlodipine to angiotensin II type 1 receptor blockers (ARBs) improved vascular function and structure in hypertensive patients. These benefits occurred independently of blood pressure reduction, suggesting amlodipine
Area of Science:
- Cardiology
- Pharmacology
- Hypertension Management
Background:
- Hypertension poses significant cardiovascular risks.
- Angiotensin II type 1 receptor blockers (ARBs) are common antihypertensives.
- Further interventions are explored for patients with controlled blood pressure.
Purpose of the Study:
- To assess if amlodipine improves cardiovascular damage in hypertensive patients already on ARBs.
- To evaluate amlodipine's effects on vascular structure and function beyond blood pressure control.
Main Methods:
- A 12-month, randomized, placebo-controlled trial.
- Evaluated cardiothoracic ratio, urinary albumin, pulse wave velocity (PWV), intima-media thickness (IMT), and 24-hour ambulatory blood pressure (BP).
- 50 hypertensive patients on ARB therapy received add-on amlodipine or placebo.
Main Results:
- Add-on amlodipine significantly improved PWV and IMT.
- No significant changes were observed in cardiothoracic ratio or urinary albumin excretion.
- Amlodipine reduced ambulatory BP variability, but this did not mediate vascular improvements.
Conclusions:
- Low-dose amlodipine offers vascular benefits in ARB-treated hypertensive patients, independent of blood pressure reduction.
- Amlodipine's antiatherogenic properties may prevent arterial stiffness progression.
- This suggests a role for amlodipine in comprehensive hypertensive management.
Abstract:
The present study was designed to determine whether adding amlodipine further improved functional and structural cardiovascular damage in hypertensive patients whose blood pressure was already well controlled with an angiotensin II type 1 receptor blocker (ARB). The cardiothoracic ratio on chest radiographs, level of urinary albumin excretion, pulse wave velocity (PWV), intima-media thickness (IMT) of the carotid arteries, and 24 hour ambulatory blood pressure (BP) were evaluated before and 12 months after the start of add-on of amlodipine or placebo in 50 hypertensive patients being treated with an ARB. The add-on amlodipine therapy significantly improved the PWV from 1689 +/- 61 to 1447 +/- 47 cm/s and the IMT from 0.88 +/- 0.08 to 0.75 +/- 0.06 mm in the hypertensive patients treated with an ARB without altering their mean 24 hour ambulatory BP values, but did not alter the cardiothoracic ratio or urinary albumin excretion. Amlodipine also significantly decreased the variability of ambulatory BP, but the decrease did not significantly contribute to the changes in PWV or IMT. Thus, the add-on low-dose amlodipine therapy had benefits in terms of the vascular function and vascular structure of hypertensive patients treated with an ARB that were independent of its depressor effects. The antiatherogenic pleiotropic properties of amlodipine have a preventive effect on the progression of arterial stiffness in hypertensive patients treated with an ARB.
Related Concept Videos
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Action of Calcium Channel Blockers
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...